Clinical trial
Sintilimab Combined With Anlotinib Therapy for Patients With Initially Unresectable Stage II-III Non-small Cell Lung Cancer: A Prospective, Single-arm Study
NCT05306847 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sintilimab Combined With Anlotinib Therapy for Patients With Initially Unresectable Stage II-III Non-small Cell Lung Cancer: A Prospective, Single-arm Study
- Lead sponsor
- Peking Union Medical College Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 1, 2022
- Completion date
- April 1, 2026
- Enrollment
- 93 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.